The pharmacological treatment of nonalcoholic fatty liver disease in children

References

• Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411–428.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16:517–530.
   PubMed Web of Science ®Google Scholar
• Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195–203.
   PubMed Web of Science ®Google Scholar
• Kleiner DE. Histopathology, grading and staging of nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2018;64:28–38.
   PubMed Web of Science ®Google Scholar
• Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol. 2013;58:1218–1229.
   PubMed Web of Science ®Google Scholar
• Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 2016;170:e161971.
   PubMed Web of Science ®Google Scholar
• Gruben N, Shiri-Sverdlov R, Koonen DP, et al. Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison? Biochim Biophys Acta. 2014;1842:2329–2343.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–649.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alkhouri N, Alisi A, et al. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr. 2015;169:170–176.
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461‐1465.
   PubMed Web of Science ®Google Scholar
• Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52:1274–1280.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013;19:6969‐6978.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Crudele A, Panera P, et al. β-Klotho gene variation is associated with liver damage in children with NAFLD. J Hepatol. 2020;72:411–419.
   PubMed Web of Science ®Google Scholar
• Vacca M, Allison M, Griffin JL, et al. Fatty acid and glucose sensors in hepatic lipid metabolism: implications in NAFLD. Semin Liver Dis. 2015;35:250–261.
   PubMed Web of Science ®Google Scholar
• Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451–464.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhou J, Liu J, et al. Metagenome of gut microbiota of children with nonalcoholic fatty liver disease. Front Pediatr. 2019;7:518.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Johnson JS, Angeles JE, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology. 2019;157:1109–1122.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther. 2014;39:3–14.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64:319–334.
   PubMed Web of Science ®Google Scholar
• Di Sessa A, Cirillo G, Guarino S, et al. Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. Pediatric Health Med Ther. 2019;10:89–97.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol. 2009;15:6017–6022.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–1112.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Lanti C, Riso P, et al. Nutritional therapy for non-alcoholic fatty liver disease. J Nutr Biochem. 2016;29:1–11.
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–1561.
   PubMed Web of Science ®Google Scholar
• Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzymes levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428–1432.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–1393.
   PubMed Web of Science ®Google Scholar
• Kesse-Guyot E, Ahluwalia N, Lassale C, et al. Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a 6-year prospective study. Nutr Metab Cardiovasc Dis. 2013;23:677–683.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143.
   PubMed Web of Science ®Google Scholar
• Della Corte C, Mosca A, Vania A, et al. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: the results of an Italian Study. Nutrition. 2017;39–40:8–14.
   PubMed Web of Science ®Google Scholar
• Van Der Heijden GJ, Wang ZJ, Chu Z, et al. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc. 2010;42:1973–1980.
   PubMed Web of Science ®Google Scholar
• Hannukainen JC, Nuutila P, Borra R, et al. Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins. J Physiol. 2007;578:347–358.
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:119–128.
   PubMed Web of Science ®Google Scholar
• Labayen I, Medrano M, Arenaza L, et al. Effects of exercise in addition to a family-based lifestyle intervention program on hepatic fat in children with overweight. Diabetes Care. 2020;43:306–313.
   PubMed Web of Science ®Google Scholar
• Treadwell JR, Sun F, Schoelles K. Systematic review and meta-analysis of bariatric surgery for pediatric obesity. Ann Surg. 2008;248:763–776.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–2693.
   PubMed Web of Science ®Google Scholar
• Rubino F, Shukla A, Pomp A, et al. Bariatric, metabolic, and diabetes surgery: what’s in a name? Ann Surg. 2014;259:117–122.
   PubMed Web of Science ®Google Scholar
• Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–388.
   PubMed Web of Science ®Google Scholar
• Xanthakos SA, Jenkins TM, Kleiner DE, et al. Teen-LABS consortium. high prevalence of nonalcoholic fatty liver disease in adolescents undergoing bariatric surgery. Gastroenterology. 2015;149:623–634.e8.
   PubMed Web of Science ®Google Scholar
• Inge TH, Courcoulas AP, Jenkins TM, et al. Teen-LABS consortium. weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374:113–123.
   PubMed Web of Science ®Google Scholar
• Manco M, Mosca A, De Peppo F, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr. 2017;180:31–37.e2.
   PubMed Web of Science ®Google Scholar
• Nobili V, Carpino G, De Peppo F, et al. Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease-related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production. J Pediatr. 2018;194:100–108.e3.
   PubMed Web of Science ®Google Scholar
• Braun HA, Faasse SA, Vos MB. Advances in pediatric fatty liver disease: pathogenesis, diagnosis, and treatment. Gastroenterol Clin North Am. 2018;47:949–968.
   PubMed Web of Science ®Google Scholar
• He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137:635–646.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550–554.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Middleton MS, Deutsch R, et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;21:871–879.
   PubMed Web of Science ®Google Scholar
• Nadeau KJ, Ehlers LB, Zeitler PS, et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009;10:5–13.
   PubMed Web of Science ®Google Scholar
• Rakoski MO, Singal AG, Rogers MA, et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010;32:1211–1221.
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Shah J, Okubote T, Alkhouri N. Overview of updated practice guidelines for pediatric nonalcoholic fatty liver disease. Gastroenterol Hepatol. 2018;14:407–414.
   Google Scholar
• Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr. 2009;48:587–596.
   PubMed Web of Science ®Google Scholar
• Panera N, Barbaro B, Della Corte C, et al. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. Nutr Res. 2018;58:1–16.
   PubMed Web of Science ®Google Scholar
• Hill DB, Devalarajan R, Joshi‐Barve S, et al. Antioxidants attenuate nuclear factor‐Kappa B activation and tumor necrosis factor‐alpha production in alcohol hepatitis patient monocytes and rat kupffer cells, in vitro. Clin Biochem. 1999;32:563–570.
   PubMed Web of Science ®Google Scholar
• Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:641–648.
   PubMed Web of Science ®Google Scholar
• Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett. 1992;308:267–270.
   PubMed Web of Science ®Google Scholar
• Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–738.
   PubMed Web of Science ®Google Scholar
• Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55.
   PubMed Web of Science ®Google Scholar
• Xin YN, Xuan SY, Zhang JH, et al. Omega-3 polyunsaturated fatty acids: a specific liver drug for non-alcoholic fatty liver disease (NAFLD). Med Hypotheses. 2008;71:820–821.
   PubMed Web of Science ®Google Scholar
• Stulnig TM. Immunomodulation by polyunsaturated fatty acids: mechanisms and effects. Int Arch Allergy Immunol. 2003;132:310–321.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23:1066–1070.
   PubMed Web of Science ®Google Scholar
• Nobili V, Carpino G, Alisi A, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014;9:e88005.
   PubMed Web of Science ®Google Scholar
• Nobili V, Bedogni G, Donati B, et al. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food. 2013;16:957–960.
   PubMed Web of Science ®Google Scholar
• Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166:1358–1363.e1–3.
   PubMed Web of Science ®Google Scholar
• Della Corte C, Carpino G, De Vito R, et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial. PLoS One. 2016;11:e0168216.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Mosca A, et al. The antioxidant effects of hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease, in a clinical trial: a new treatment? Antioxid Redox Signal. 2019;31:127–133.
   PubMed Web of Science ®Google Scholar
• Li Z, Vance DE. Phosphatidylcholine and choline homeostasis. J Lipid Res. 2008;49:1187–1194.
   PubMed Web of Science ®Google Scholar
• Li Z, Agellon LB, Alle TM, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006;3:321–331.
   PubMed Web of Science ®Google Scholar
• Zohrer E, Alisi A, Jahnel J, et al. Efficacy of docosahexaenoic acid–choline–vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab. 2017;42:948–954.
   PubMed Web of Science ®Google Scholar
• Pathil A, Mueller J, Warth A, et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55:1369–1378.
   PubMed Web of Science ®Google Scholar
• Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739–743.
   PubMed Web of Science ®Google Scholar
• Dohil R, Meyer L, Schmeltzer S, et al. The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects. J Pediatr. 2012;161:639–45.e1.
   PubMed Web of Science ®Google Scholar
• Dohil R, Schmeltzer S, Cabrera BL, et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:1036–1044.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Lavine JE, Laura A, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016;151:1141–1154.e9.
   PubMed Web of Science ®Google Scholar
• Sabaté JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18:371–377.
   PubMed Web of Science ®Google Scholar
• Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887.
   PubMed Web of Science ®Google Scholar
• Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–350.
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Distrutti E, Renga B, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6:e22978.
   PubMed Web of Science ®Google Scholar
• Vajro P, Mandato C, Licenziati MR, et al. Effects of lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740–743.
   PubMed Web of Science ®Google Scholar
• Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285.
   PubMed Web of Science ®Google Scholar
• Nobili V, Putignani L, Mosca A, et al. Bifidobacteria and Lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? Arch Med Sci. 2018;14:81–87.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754–1767.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Elafibranor, PK and safety in children and adolescents 8 to 17 years of age with non alcoholic steatohepatitis (NASH). ClinicalTrialsGov; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03883607
   Google Scholar
• Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): review of phase 2 and 3 trials. J Clin Transl Hepatol. 2018;6:264–275.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26–39.
   PubMed Web of Science ®Google Scholar
• Liyanagedera S, Williams RP, Veraldi S, et al. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol. 2017;10:1225–1237.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal AJ, Loomba R, et al. REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019;84:105803.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Neuschwander-Tetri BA, Wong VW, et al. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials. 2020;89:105922.
   PubMed Web of Science ®Google Scholar
• Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future. World J Hepatol. 2015;7:2597–2602.
   PubMed Web of Science ®Google Scholar